Cargando…

Botulinum Neurotoxin A in the Treatment of Pharyngocutaneous Fistula after Salvage Surgery in Head and Neck Cancer Patients: Our Preliminary Results

Objective: To analyze the effect of intraparotid injection of botulinum neurotoxin A (BoNT-A) on salivary production and the course of pharyngocutaneous fistula (PCF) in post-radiation therapy salvage surgery. Methods: A total of 13 patients who had undergone total laryngectomy or pharyngolaryngecto...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchese, Maria Raffaella, Di Cesare, Tiziana, De Corso, Eugenio, Petracca, Martina, Oliveto, Giuseppe, Almadori, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601243/
https://www.ncbi.nlm.nih.gov/pubmed/36290834
http://dx.doi.org/10.3390/curroncol29100557
_version_ 1784817010973081600
author Marchese, Maria Raffaella
Di Cesare, Tiziana
De Corso, Eugenio
Petracca, Martina
Oliveto, Giuseppe
Almadori, Giovanni
author_facet Marchese, Maria Raffaella
Di Cesare, Tiziana
De Corso, Eugenio
Petracca, Martina
Oliveto, Giuseppe
Almadori, Giovanni
author_sort Marchese, Maria Raffaella
collection PubMed
description Objective: To analyze the effect of intraparotid injection of botulinum neurotoxin A (BoNT-A) on salivary production and the course of pharyngocutaneous fistula (PCF) in post-radiation therapy salvage surgery. Methods: A total of 13 patients who had undergone total laryngectomy or pharyngolaryngectomy were treated with BoNT-A to both parotid glands, within three days from PCF onset. The salivary flow was evaluated using a subjective rating scale as the percentage of normal function from 0% (no saliva) to 100% (normal saliva flow), before injection, every day for 2 weeks, and once a week for three months. PCFs were monitored daily. Results: Spontaneous closure of PCF occurred in 7/13 (53.84%) cases 13.6 days (range: 7–18) after treatment; 6/13 (46.16%) patients needed revision surgery. Salivary flow significantly decreased in all patients seven days after injection (from 67.2% to 36.4%; p < 0.05). Patients who had undergone either conservative or surgical treatment did not differ in salivary flow before injection, whereas the mean percentages of salivary flow calculated at each time point after injection were different (p < 0.05). Conclusions: BoNT-A contributed to the closure of the fistula in most of our cases. The subjective perception of salivary flow predicted the closure of PCF. The mean time to closure may contribute to establishing the timing of PCF surgical treatment.
format Online
Article
Text
id pubmed-9601243
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96012432022-10-27 Botulinum Neurotoxin A in the Treatment of Pharyngocutaneous Fistula after Salvage Surgery in Head and Neck Cancer Patients: Our Preliminary Results Marchese, Maria Raffaella Di Cesare, Tiziana De Corso, Eugenio Petracca, Martina Oliveto, Giuseppe Almadori, Giovanni Curr Oncol Article Objective: To analyze the effect of intraparotid injection of botulinum neurotoxin A (BoNT-A) on salivary production and the course of pharyngocutaneous fistula (PCF) in post-radiation therapy salvage surgery. Methods: A total of 13 patients who had undergone total laryngectomy or pharyngolaryngectomy were treated with BoNT-A to both parotid glands, within three days from PCF onset. The salivary flow was evaluated using a subjective rating scale as the percentage of normal function from 0% (no saliva) to 100% (normal saliva flow), before injection, every day for 2 weeks, and once a week for three months. PCFs were monitored daily. Results: Spontaneous closure of PCF occurred in 7/13 (53.84%) cases 13.6 days (range: 7–18) after treatment; 6/13 (46.16%) patients needed revision surgery. Salivary flow significantly decreased in all patients seven days after injection (from 67.2% to 36.4%; p < 0.05). Patients who had undergone either conservative or surgical treatment did not differ in salivary flow before injection, whereas the mean percentages of salivary flow calculated at each time point after injection were different (p < 0.05). Conclusions: BoNT-A contributed to the closure of the fistula in most of our cases. The subjective perception of salivary flow predicted the closure of PCF. The mean time to closure may contribute to establishing the timing of PCF surgical treatment. MDPI 2022-09-28 /pmc/articles/PMC9601243/ /pubmed/36290834 http://dx.doi.org/10.3390/curroncol29100557 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Marchese, Maria Raffaella
Di Cesare, Tiziana
De Corso, Eugenio
Petracca, Martina
Oliveto, Giuseppe
Almadori, Giovanni
Botulinum Neurotoxin A in the Treatment of Pharyngocutaneous Fistula after Salvage Surgery in Head and Neck Cancer Patients: Our Preliminary Results
title Botulinum Neurotoxin A in the Treatment of Pharyngocutaneous Fistula after Salvage Surgery in Head and Neck Cancer Patients: Our Preliminary Results
title_full Botulinum Neurotoxin A in the Treatment of Pharyngocutaneous Fistula after Salvage Surgery in Head and Neck Cancer Patients: Our Preliminary Results
title_fullStr Botulinum Neurotoxin A in the Treatment of Pharyngocutaneous Fistula after Salvage Surgery in Head and Neck Cancer Patients: Our Preliminary Results
title_full_unstemmed Botulinum Neurotoxin A in the Treatment of Pharyngocutaneous Fistula after Salvage Surgery in Head and Neck Cancer Patients: Our Preliminary Results
title_short Botulinum Neurotoxin A in the Treatment of Pharyngocutaneous Fistula after Salvage Surgery in Head and Neck Cancer Patients: Our Preliminary Results
title_sort botulinum neurotoxin a in the treatment of pharyngocutaneous fistula after salvage surgery in head and neck cancer patients: our preliminary results
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601243/
https://www.ncbi.nlm.nih.gov/pubmed/36290834
http://dx.doi.org/10.3390/curroncol29100557
work_keys_str_mv AT marchesemariaraffaella botulinumneurotoxinainthetreatmentofpharyngocutaneousfistulaaftersalvagesurgeryinheadandneckcancerpatientsourpreliminaryresults
AT dicesaretiziana botulinumneurotoxinainthetreatmentofpharyngocutaneousfistulaaftersalvagesurgeryinheadandneckcancerpatientsourpreliminaryresults
AT decorsoeugenio botulinumneurotoxinainthetreatmentofpharyngocutaneousfistulaaftersalvagesurgeryinheadandneckcancerpatientsourpreliminaryresults
AT petraccamartina botulinumneurotoxinainthetreatmentofpharyngocutaneousfistulaaftersalvagesurgeryinheadandneckcancerpatientsourpreliminaryresults
AT olivetogiuseppe botulinumneurotoxinainthetreatmentofpharyngocutaneousfistulaaftersalvagesurgeryinheadandneckcancerpatientsourpreliminaryresults
AT almadorigiovanni botulinumneurotoxinainthetreatmentofpharyngocutaneousfistulaaftersalvagesurgeryinheadandneckcancerpatientsourpreliminaryresults